Loading patent…
AssigneeAdjutec Pharma AS
InventorsPål RONGVED, Bjørn KLEM
Estimating the term…
The invention provides a method of treatment of a bacterial infection which comprises co-administration of an effective amount of each of the following agents to a subject in need thereof: (A) a selective zinc-chelator which comprises one or more lipophilic, zinc chelating moieties covalently bound to one or more hydrophilic moieties, wherein said zinc chelating moieties are selective for Zn2+ ions and wherein said hydrophilic moieties are selected from hydrophilic monomeric, oligomeric and polymeric groups; (B) a p-lactam antibiotic selected from the group consisting of penicillins, monobactams and carbapenems; and (C) a serine β-lactamase inhibitor. Pharmaceutical compositions and kits which comprise a combination of agents (A), (B) and (C) are so provided.
A method of treatment of a bacterial infection, said method comprising co-administration of an effective amount of each of the following agents to a subject in need thereof:
A method of treatment as claimed in 12, wherein the sugar moiety is a cyclic or acyclic monosaccharide, preferably wherein the sugar moiety is selected from the following groups and their stereoisomers:
A method of treatment as claimed in any one of the preceding claims, wherein agent (C) is a serine β-lactamase inhibitor which inhibits at least one SBL in Ambler class A, for example CepA, KPC-2, IMI-1, SME-1, PC1, TEM-1, TEM-2, TEM-3, TEM-30, TEM-50, SHV-1, SHV-2, SHV-10, CTX-M-15, PER-1, VEB-1, PSE-1, CARB-3, or RTG-4;
A method of treatment as claimed in any one of the preceding claims, wherein the serine β-lactamase inhibitor is a diaza-bicyclo-octanone (DBO) compound, a prodrug or a pharmaceutically acceptable salt thereof.
A method of treatment as claimed in any one of the preceding claims, wherein the bacterial infection is associated with gram-positive or gram-negative bacteria, preferably gram-negative bacteria, more preferably wherein said bacteria are resistant to treatment with one or more antibiotics, particularly bacteria that are resistant to treatment with β-lactam antibiotics.
A method of treatment as claimed in any one of the preceding claims, wherein the bacterial infection is caused by a bacteria selected from the group consisting of Acinetobacter baumannii, Acinetobacter calcoaceticus, Acinetobacter haemolyticus, Aeromonas spp, Aeromones hydrophilia, Bacillus cereus Bacteroides fragilis, Bacteroides distasonis, Bacteroides 3452A homology group, Bacteroides vulgatus, Bacteroides ovalus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides eggerthii, Bacteroides splanchnicus, Bacteroides thetaiotaomicron, Borrelia burgdorferi, Bordetella pertussis, Bordetella parapertussis, Bordetella bronchiseptica, Burkholderia cepacia, Branhamella catarrhalis, Campylobacterfetus, Campylobacter jejuni, Campylobacter coli, Chryseobacterium indologenes Citrobacter freundii, Clostridium difficile, Corynebacterium diphtheriae, Corynebacterium ulcerans, Elizabethkingia meningoseptica, Escherichia coli, Enterobacter cloacae, Enterobacter aerogenes, Enterococcus faecalis, Enterococcus faecium, Francisella tularensis, Gardnerella vaginalis, Haemophilus influenzae, Haemophilus parainfluenzae, Haemophilus haemolyticus, Haemophilus parahaemolyticus, Haemophilus ducreyi, Helicobacter pylori, Legionella pneumophila, Listeria monocytogenes, Kingella, Moraxella, Klebsiella pneumoniae, Klebsiella oxytoca, Legionella pneumophila, Listeria monocytogenes, Morganella morganii, Mycobacterium tuberculosis, Mycobacterium avium, Mycobacterium intracellulare, Moraxella, Mycobacterium leprae, Myroides odoratimimus, Neisseria gonorrhoeae, Neisseria meningitidis Pasteurella multocida, Pasteurella haemolytica, Proteus mirabilis, Proteus vulgaris, Providencia alcalifaciens, Providencia rettgeri, Providencia stuartii, Pseudomonas fluorescens, Pseudomonas aeruginosa, Pseudomonasfluorescens, Pseudomonas acidovorans, Pseudomonas alcaligenes, Pseudomonasputida, Serratia marcescens, Salmonella typhimurium, Salmonella typhi, Salmonella paratyphi, Salmonella enteritidis, Serratia marcescens, Shigella dysenteriae, Shigella flexneri, Shigella sonnei, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus saprophyticus, Staphylococcus intermedius, Staphylococcus hyicus subsp. hyicus, Staphylococcus haemolyticus, Staphylococcus hominis, Staphylococcus saccharolyticus. Stenotrophomonas maltophilia, Streptococcus pneumoniae, Streptococcus agalactiae, Streptococcus pyogenes, Vibrio cholerae, Vibrio parahaemolyticus, Yersinia pestis, Yersinia pseudotuberculosis, Yersinia intermedia, Yersinia enterocolitica, and Yersinia pestis.
A method of treatment as claimed in any one of the preceding claims, wherein the subject is a human.
Dependencies are inferred from the claim text.